Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Maine first, probably not last

WASHINGTON - High drug costs, especially for senior citizens, is gaining traction as one of the most significant political issues for the U.S. elections in November, and with the prospect for federal action uncertain, state legislatures across the country are stirring. Maine is furthest along, but other, more populous states are not far behind.

Both houses of the Maine state assembly

Read the full 601 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE